Electrical stimulation for limb spasticity in children with stroke
A protocol for systematic review

Jing Nie, MM, He Wang, MM, Quan-wei Jiang, MM, Ying Zhang, MB, Zhi-guang Zhang, MM, Mei Mei, MM*

Abstract
Background: This systematic review protocol will appraise the effectiveness and safety of electrical stimulation (ES) for limb spasticity (LS) in children with stroke.

Methods: Cochrane Library, EMBASE, PUBMED, PsycINFO, Scopus, OpenGrey, CINAHL, ACMd, CNKI, and WANGFANG will be systematically retrieved for randomized controlled trials (RCTs) testing the effectiveness of ES compared with other interventions on LS in children with stroke. Two independent authors will evaluate eligibility using predefined criteria and will perform data extraction and study quality appraisal of eligible trials. Primary outcomes include gait velocity, and limb spasticity status. Limb function, quality of life, pain intensity, and adverse events will be assessed as secondary outcomes. We will perform data analysis using RevMan 5.3 software.

Results: This systematic review will summarize the most recent evidence to assess the effectiveness and safety of ES for LS in children with stroke.

Conclusions: The results of this study may help to determine whether ES is effective or not for LS in children with stroke.

Study registration: INPLASY202050115.

Abbreviations: CIs = confidence intervals, ES = electrical stimulation, LS = limb spasticity, RCTs = randomized controlled trials.

Keywords: effectiveness, electrical stimulation, limb spasticity, safety, stroke

1. Introduction
Stroke is a leading cause of death and disability around the world. Most stroke survivors often develop motor dysfunction and limb spasticity, which significantly limit their mobility and functional ability, and thus affect quality of life. It has been estimated that its incidence varies from 17% to 38%. Given such severe conditions, effective treatments are necessary to manage their rehabilitation. However, few effective interventions have been developed in treating spasticity post stroke, especially in children population.

Previous studies have reported that electrical stimulation (ES) has been found to decrease limb spasticity (LS) following stroke. However, no systematic review supports the use of ES for LS in children after stroke. Thus, the present systematic review protocol will target to evaluate the effectiveness and safety of ES for relieving post stroke LS in children population.

2. Methods and analysis
2.1. Study registration
This study was registered at INPLASY (INPLASY202050115), and it is reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.

2.2. Ethics and dissemination
This study will not require ethic approval, because it will be conducted based on published studies. We will publish this study on a peer-reviewed journal or relevant conference.

3. Inclusion criteria for study selection
3.1. Type of studies
This systematic review will consider randomized controlled trials (RCTs) on effectiveness and safety of ES for LS in children with stroke for inclusion. We will exclude animal study, review,
editorial letter, comment, case report, case series, uncontrolled trial, and quasi-RCTs.

3.2. Type of participants
All children under 18 years old with LS following stroke will be included, in spite of ethnicity, country, and severity of LS and stroke.

3.3. Type of interventions
In the experimental group, all patients received any types of ES, such as neuromuscular electrical stimulation, transcutaneous electrical nerve stimulation, and electroacupuncture.

In the control group, no restrictions will be applied to any comparators. However, we will not consider any types of ES.

3.4. Type of outcomes
Primary outcomes are gait velocity (as assessed by Gait Velocity Assessment Toolkit or other scales), and limb spasticity status (as evaluated by Modified Ashworth Scale or other tools).

Secondary outcomes are limb function (as appraised by Disability Assessment Scale or other scales), quality of life (as detected by 36-Item Short Form Survey or other surveys), pain intensity (as measured by Visual Analogue Scale or other scales), and adverse events.

3.5. Search strategy
A systematic search will be performed from inception to the present without language and publication status limitations in Cochrane Library, EMBASE, PUBMED, PsycINFO, Scopus, OpenGrey, CINAHL, ACMD, CNKI, and WANGFANG. All eligible RCTs testing the effectiveness and safety of ES on LS in children with stroke will be included. We will build detailed search strategy for Cochrane Library in Table 1, and will adapt similar retrieval strategies for other electronic databases. In addition, this study will examine other sources, such as conference information, ongoing, or unpublished studies from clinical trial registry, and reference lists of relevant reviews.

4. Data collection and management

4.1. Study selection
Two independent authors will import all searched citations into EndNote X8 to remove duplicates. At first, we will read titles/abstracts to eliminate any irrelevant record. Then, we will carefully identify full-text of remaining potential studies against all eligibility criteria. Any doubt will be clarified by a third author through discussion and consensus. Studies excluded will be noted with reasons for their exclusion. We will present selection of study procedure in a flow diagram.

4.2. Data extraction and management
Using a predefined and developed data extraction form, 2 independent authors will extract data from all eligible RCTs. Any disagreement will be solved by a third author via discussion. We will extract following information: first author, journal/source, country, year of publication, trial design, setting, sample size, diagnostic criteria, inclusion/exclusion criteria, details of ES and controls, outcomes, adverse events, results, findings, follow-up information, and conflict of interest.

4.3. Missing data dealing with
If we identify any insufficient or unclear or missing data, we will obtain them by contacting primary authors through email. We will analyze available data if we can not obtain that data.

4.4. Study quality assessment
Two independent authors will appraise study quality for eligible RCTs using Cochrane Risk of Bias Tool with predetermined criteria. Each study will be rated as a high, unclear or low risk of bias. Any divergence will be solved by a third author through consensus.

| Table 1 | Search strategy for Cochrane Library. |
| Number | Search terms |
|--------|-------------|
| 1      | MeSH descriptor: (stroke) explode all trees |
| 2      | (post-stroke) or (cerebrovascular) or (brain vascular) or (cerebral vascular) or (apoplexy) or (ischemic injury]):ti, ab, kw |
| 3      | Or 1–2 |
| 4      | MeSH descriptor: (extremities) explode all trees |
| 5      | MeSH descriptor: (muscle spasticity) explode all trees |
| 6      | (extremities) or (limbs) or (limbs) or (extremities spasticity) or (limb spasticity):ti, ab, kw |
| 7      | Or 4–6 |
| 8      | MeSH descriptor: (electric stimulation) explode all trees |
| 9      | MeSH descriptor: (transcutaneous electric nerve stimulation) explode all trees |
| 10     | MeSH descriptor: (electroacupuncture) explode all trees |
| 11     | (electric stimulation) or (electric stimulation) or (electrotherapy) or (transcutaneous) or (transcutaneous electrical stimulation) or (transcutaneous nerve stimulation) or (electroacupuncture) or (electrical) or (stimulation):ti, ab, kw |
| 12     | Or 8-11 |
| 13     | MeSH descriptor: (randomized controlled trials) explode all trees |
| 14     | (random) or (allocation) or (random allocation) or (placebo) or (single blind) or (double blind) or (double blind) or (randomized control trial) or (RCT) or (clinical trials) or (controlled clinical trials):ti, ab, kw |
| 15     | Or 13–14 |
| 16     | 3 and 7 and 12 and 15 |
4.5. Statistical analysis

We will utilize RevMan 5.3 software to pool and analyze data. All dichotomous outcomes will be estimated as relative risk/relative risk ratio with 95% confidence intervals (CIs); and continuous outcomes will be calculated as weighted mean difference with 95% CIs. Statistical heterogeneity will be examined using I² test. Values of I² are less than 50% will be considered as minor heterogeneity, while I² values over 50% will be suggested as significant heterogeneity. We will carry out meta-analysis if minor heterogeneity is tested and sufficient data is extracted. Otherwise, we will perform descriptive analyses for those studies which are deemed clinically heterogeneous or aggregate data for synthesizing.

4.6. Subgroup analysis

Where applicable, we will conduct subgroup analysis or meta-regression for factors presumed to cause significant heterogeneity or variations in study characteristics, details of interventions and controls, and outcome indicators.

4.7. Sensitivity analysis

Whenever possible, we will perform sensitivity analysis to test robustness and stability of study findings based on study quality, sample size and missing, or insufficient data.

4.8. Reporting bias

When over 10 RCTs are included, we will check reporting bias using funnel plot,[29] and Egger linear regression test.[30]

5. Discussion

LS is one of the most common complications in post stroke survivors. Although ES is utilized in the clinical treatment of LS, its effectiveness and safety in children with stroke continues to be debated. Recent studies have provided increasing evidence in this field; however, no systematic review has addressed this issue. The present study will summarize high quality RCTs to evaluate the effectiveness and safety of ES in treating LS in children following stroke. The results of this study will help to determine whether ES is effective or not for the treatment of LS in children with stroke, which may benefit both patients and clinical practice.

Author contributions

Conceptualization: Jing Nie, He Wang, Quan-wei Jiang.
Data curation: He Wang, Ying Zhang, Zhi-guang Zhang.
Formal analysis: Jing Nie, Quan-wei Jiang, Ying Zhang.
Methodology: Jing Nie, Quan-wei Jiang, Ying Zhang, Zhi-guang Zhang.
Resources: Jing Nie, He Wang, Quan-wei Jiang, Ying Zhang, Zhi-guang Zhang.
Software: Jing Nie, He Wang, Quan-wei Jiang, Ying Zhang, Zhi-guang Zhang.
Validation: Jing Nie, He Wang, Ying Zhang, Zhi-guang Zhang.
Visualization: Jing Nie, Quan-wei Jiang, Ying Zhang.
Writing – original draft: Jing Nie, He Wang, Ying Zhang, Zhi-guang Zhang.
Writing – review & editing: Jing Nie, Quan-wei Jiang.

References

[1] Baylan S, Griffiths S, Grant N, et al. Incidence and prevalence of post-stroke insomnia: a systematic review and meta-analysis. Sleep Med Rev 2020;49:101222.
[2] Loh AZ, Tan JS, Zhang MW, et al. The global prevalence of anxiety and depressive symptoms among caregivers of stroke survivors. J Am Med Dir Assoc 2017;18:111–6.
[3] Fonville S, Zandbergen AA, Koudstaal PJ, et al. Prediabetes in patients with stroke or transient ischemic attack: prevalence, risk and clinical management. Cerebrovasc Dis 2014;37:395–400.
[4] Stinear CM, Barber PA, Penoe M, et al. The PREP algorithm predicts potential for upper limb recovery after stroke. Brain 2012;135(Pt 8):2527–35.
[5] Sommerfeld DK, Gripenstedt U, Welmer AK. Spasticity after stroke: an overview of prevalence, test instruments, and treatments. Am J Phys Med Rehabil 2012;91:814–20.
[6] Santamato A, Cinone N, Panza F, et al. Botulinum toxin type A for the treatment of lower limb spasticity after stroke. Drugs 2019;79:143–60.
[7] Gupta AD, Chu WH, Howell S, et al. A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity. Syst Rev 2018;7:1.
[8] Dymarck R, Ptaszkowski K, Supka L, et al. Effects of extracorporeal shock wave on upper and lower limb spasticity in post-stroke patients: a narrative review. Top Stroke Rehabil 2016;23:293–303.
[9] Lundstrom E, Terent A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008;15:533–9.
[10] Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil 2002;16:515–22.
[11] Sommerfeld DK, Ekk EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004;35:134–9.
[12] Wang HQ, Hou M, Bao CL, et al. Effects of acupuncture treatment on lower limb spasticity in patients following hemorrhagic stroke: a pilot study. Eur Neurol 2019;81:5–12.
[13] Francisco GE, McGuire JR. Poststroke spasticity management. Stroke 2012;43:3152–6.
[14] Wang M, Liu S, Peng Z, et al. Effect of Tui Na on upper limb spasticity after stroke: a randomized clinical trial. Ann Clin Transl Neuro 2019;6:778–87.
[15] Xi M, Zhou G, Luo M, et al. Blood-letting and cupping therapy for upper limb spasticity in recovery phase of stroke. Zhongguo Zhen Jiu 2018;38:1145–9.
[16] Marciniak C, Munin MC, Brashier A, et al. IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: results from the open-label extension period of a phase 3 study. Adv Ther 2019;36:187–99.
[17] He YL, Gao Y, Fan BY. Effectiveness of neuromuscular electrical stimulation combined with rehabilitation training for treatment of post-stroke limb spasticity. Medicine (Baltimore) 2019;98:e17261.
[18] Rousseaux M, Bussert N, Daveluy W, et al. Long-term effect of tibial nerve neurotomy in stroke patients with lower limb spasticity. J Neurol Sci 2009;278:73–6.
[19] Rheodorff K, Dressler D, Woldag H, et al. Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A: results of the German-Austrian subgroup of the ULIS-II study. Nervenarzt 2019;90:361–70.
[20] Huang HY, Du HW, Chen C, et al. Rehabilitation effects of low-frequency rTMS combined with FES on lower limb spasm and motor function in patients with subacute ischemic stroke. J Cardiovasc Rehab Med 2019;36(5):317–9.
[21] Liu XJ, Wang M, Zhu GQ. The clinical effect of MOTOMed intelligent training combined with spastic muscle electrical stimulation on lower limb muscle spasm in stroke patients. J Bengbu Med Coll 2019;44:317–9.
[22] Wang Y, Xi JY, Zong LC, et al. Observation of the therapeutic effect of low-frequency neuromuscular electrical stimulation combined with baclofen in the treatment of stroke hemiplegia patients with muscle spasm. Journal of Practical Heart, Brain. Pulmon Vasc Dis 2018;26:80–3.
[23] Ren HW, Wang EL. Clinical observation of electroacupuncture antagonist muscle combined with rehabilitation therapy for 68 patients with increased muscle tone after stroke. Clinic J Trad Chin Med 2017;29:1752–4.
[24] Sun XY. A randomized parallel controlled study on the effect of electroacupuncture combined with meridian acupuncture on the motor function of spastic limbs and daily life after stroke. J Pract Trad Chin Med 2014;28:138–40.
[25] Chen QQ, Cao S, Kou YY, et al. Clinical research progress of electroacupuncture treatment of spastic paralysis after stroke. China Rehab 2013;28:390–1.
[26] Geng JD. Clinical study on electroacupuncture treatment of limb spasm in stroke hemiplegia. Chin J Trauma Disab Med 2012;20:97–8.
[27] Hu ZH, Gu XY. Observation on the therapeutic effect of electro-acupuncture on hemiplegic spasm of stroke. Chin Acupunct Moxibust 1999;4:13–4.
[28] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[29] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[30] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.